文献速递临床生化分子诊断质量管理与危急值

超越血压:AI辅助多组学生物标志物分层用于高血压卒中风险的临床化学、分析验证与转化展望

Beyond blood pressure: AI-assisted multi-omics biomarker stratification for stroke risk in hypertension: clinical chemistry, analytical validation, and translational perspectives.
PubMed 文献 · Clin Chim Acta · 2026-10-09

本文为综述,汇总基因组、表观基因组、转录组、蛋白质组、代谢组、脂质组、细胞外囊泡标志物及临床化学方法与AI辅助整合在高血压卒中风险生物学分层中的证据,按生物学相关性、分析就绪度、验证状态与转化潜力综合归纳。结论认为多组学可提供血管重塑、内皮功能障碍等互补信息,但生物关联不等于预测效度,预测性能不等于临床效用,常规落地前需分析验证、标准化流程、外部验证与临床效用证据。

要点

  • 多组学可补充血压之外的血管、炎症、代谢等信息,但需外部验证与临床效用证据。
  • 生物关联不等于预测效度,预测性能本身不等于临床效用。
  • 落地前提包括分析验证、标准化流程与前瞻性临床效用研究。

核心结论

  • 多组学生物标志物为理解高血压卒中风险的生物学异质性提供有前景的框架。
  • 未来研究应优先标准化测量、前瞻性验证并证明临床效用,之后才考虑常规实施。

研究设计与样本

  • 综述:检索基因组、表观基因组、转录组、蛋白质组、代谢组、脂质组、细胞外囊泡标志物、临床化学方法及AI辅助整合的相关文献。
  • 按生物学相关性、分析就绪度、验证状态与转化潜力综合归纳证据。

主要发现

  • 多组学方法可提供血管重塑、内皮功能障碍、炎症、氧化应激、血栓形成、代谢及靶器官损伤等方面的互补信息。
  • 生物关联不必然建立预测效度,预测性能本身不能证明临床效用。
  • 转化需要分析验证、标准化工作流程、外部验证及改善临床决策的证据。

临床怎么用

  • 原文未给出可直接用于检验科的具体检测项目、阈值或分层规则,转化应用需以分析验证与临床效用证据为前提。

局限性

  • 多数候选标志物仍处于探索或早期转化阶段。
  • 局限包括分析变异、外部验证有限及前瞻性临床效用研究不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension remains a major contributor to stroke burden; however, conventional blood pressure measurements do not fully capture the heterogeneous biological processes underlying cerebrovascular risk. Residual risk may persist despite apparently controlled blood pressure due to vascular, inflammatory, metabolic, cardiac, renal, and neurovascular abnormalities. OBJECTIVE: This review summarizes emerging multi-omics biomarker strategies for biological stratification of stroke risk in hypertension, emphasizing mechanistic interpretation, analytical validation, artificial intelligence (AI)-assisted integration, and clinical translation. METHODS: Relevant literature on genomic, epigenomic, transcriptomic, proteomic, metabolomic, lipidomic, extracellular vesicle biomarkers, clinical chemistry approaches, and AI-assisted integration was reviewed. Evidence was synthesized according to biological relevance, analytical readiness, validation status, and translational potential. KEY FINDINGS: Multi-omics approaches provide complementary information regarding vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, thrombosis, metabolism, and target-organ injury. However, biological associations do not necessarily establish predictive validity, and predictive performance alone does not demonstrate clinical utility. Translation requires analytical validation, standardized workflows, external validation, and evidence of improved clinical decision-making. LIMITATIONS: Most proposed biomarkers remain in exploratory or early translational stages, with limitations including analytical variability, limited external validation, and insufficient prospective clinical utility studies. CONCLUSIONS: Multi-omics biomarkers offer a promising framework for understanding biological heterogeneity in hypertensive stroke risk. Future studies should prioritize standardized measurement, prospective validation, and demonstration of clinical utility before routine implementation.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Gao Z, Li J, Jiang D, et al. Beyond blood pressure: AI-assisted multi-omics biomarker stratification for stroke risk in hypertension: clinical chemistry, analytical validation, and translational perspectives. Clin Chim Acta. 2026. PMID: 42855111. doi:10.1016/j.cca.2026.122885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。